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Background-—We prospectively assessed sex-speciﬁc differences in health perception, overall symptom status, and speciﬁc
symptoms in a large cohort of patients with atrial ﬁbrillation.
Methods and Results-—We performed a prospective multicenter observational cohort study of 1553 patients with atrial ﬁbrillation.
Patients completed questionnaires about personal characteristics, comorbidities, and symptoms on a yearly basis. Mean age was
7011 years among women and 6712 years among men. Health perception on a visual analogue scale ranging from 0 to 100
(with higher scores indicating better health perception) was signiﬁcantly lower in women than in men (70 [interquartile range: 50–
80] versus 75 [interquartile range: 60–85]; P<0.0001). More women than men had any symptoms (85.0% versus 68.3%; P<0.0001),
palpitations (65.2% versus 44.4%; P<0.0001), dizziness (25.6% versus 13.5%; P<0.0001), dyspnea (35.7% versus 21.8%; P<0.0001),
and fatigue (25.3% versus 19.1%; P=0.006). At 1-year follow-up, symptoms decreased in both sexes but remained more frequent in
women (49.1% versus 32.6%, P<0.0001). In multivariable adjusted longitudinal regression models, female sex remained an
independent predictor for lower health perception (ß=4.8; 95% CI, 6.5 to 3.1; P<0.0001), any symptoms (odds ratio [OR]: 2.6;
95% CI, 2.1–3.4; P<0.0001), palpitations (OR: 2.6; 95% CI, 2.1–3.2; P<0.0001), dizziness (OR: 2.9; 95% CI, 2.1–3.9; P<0.0001),
dyspnea (OR: 2.1; 95% CI, 1.6–2.8; P<0.0001), fatigue (OR: 1.6; 95% CI, 1.2–2.2; P=0.0008), and chest pain (OR: 1.8; 95% CI, 1.3–
2.6; P=0.001).
Conclusions-—Women with atrial ﬁbrillation have a substantially higher symptom burden and lower health perception than men.
These relationships persisted after multivariable adjustment and during prospective follow-up. ( J Am Heart Assoc. 2017;6:
e005401. DOI: 10.1161/JAHA.116.005401.)
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A trial ﬁbrillation (AF) is the most common sustainedcardiac arrhythmia in the population,1 and the number of
affected individuals is expected to double until 2060.2
Patients with AF have an increased risk of developing stroke,
heart failure, cognitive dysfunction, and death, further under-
scoring the public health importance of the arrhythmia.3–6 A
recent meta-analysis highlighted a higher risk of adverse
outcomes in women compared with men.7
In addition to an increased risk of cardiovascular events
and death, patients with AF also have poor quality of life and
high prevalence of symptoms related to either the arrhythmia
or the underlying structural heart disease.8–10 Less evidence
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is available about sex-speciﬁc differences in symptom status
or overall health perception in AF patients. Symptoms related
to AF include palpitations, dyspnea, chest pain, dizziness, and,
less commonly, syncope, fatigue, and anxiety.9 Some studies
reported that women were more symptomatic than men.10,11
A recent meta-analysis pointed out that asymptomatic AF is
more often associated with male sex, regardless of age.12
However, none of these studies performed multivariable
adjustment to correct for potential confounders. Conse-
quently, it is currently unclear whether sex is an independent
predictor of symptom status or whether the increased
symptom burden among women is due to their older
age11,13 or an increased prevalence of risk factors and/or
comorbidities. Finally, it is also relatively unknown whether
these potential sex-related differences persist during prospec-
tive follow-up.
To address some of these issues, we evaluated sex-related
differences in overall health perception and various symptom
categories at baseline and during prospective follow-up in a
large and unselected cohort of patients with AF.
Methods
BEAT-AF (Basel Atrial Fibrillation Cohort) is an ongoing
prospective, observational, multicenter cohort study. Between
2010 and 2014, 1553 patients with documented AF were
enrolled across 7 centers in Switzerland. All patients were
required to have AF that was previously documented by ECG,
rhythm strip, or device interrogation. Exclusion criteria were the
inability to sign informed consent and the exclusive presence of
short transient episodes of AF (eg, AF after cardiac surgery). For
the purpose of this study, we excluded 11 (0.7%) patients
because of missing symptom data at baseline, such that 1542
(99.5%) patients remained in the analysis. The study protocol
was approved by the local ethics committees, and informed
written consent was obtained from each participant.
Assessments
Patients completed detailed questionnaires about personal,
medical, nutritional, and lifestyle factors. Symptoms poten-
tially related to AF included palpitations, dyspnea, fatigue,
dizziness, chest pain, effort intolerance, and syncope. Overall
symptoms included the presence of at least 1 of these
symptoms. Overall health perception was self-assessed by the
participants using a visual analogue scale (VAS) ranging from
0 (worst) to 100 (best). The VAS used in this study is very
similar to the Euro-Quol VAS, which has been validated
extensively, including in patients with AF.14–16 Body mass
index was calculated as weight in kilograms divided by height
in meters squared. All participants underwent recording of a
resting 12-lead ECG.
Echocardiography was not mandatory in BEAT-AF; however,
information on left ventricular ejection fraction from a transtho-
racic echocardiogram obtained not more than 3 months before
enrollment was available for 567 (36.8%) patients.
Follow-up Examinations
Yearly follow-up examinations were performed in all patients
by mail and phone interviews. Patients completed information
about personal, nutritional, and lifestyle factors and health
perception on paper-based, mailed questionnaires. Trained
study personnel subsequently completed questionnaires on
symptoms potentially related to AF, updated comorbidities,
medication use, and intercurrent adverse events by phone.
For the present analysis, we used all data up to the 3-year
follow-up examination, as available in August 2015. At that
time, 1-year follow-up was available for 90.1% of the
participants, 2-year follow-up was available for 64.9%, and
3-year follow-up was available for 38.1%.
Statistical Analysis
Baseline and symptom characteristics were stratiﬁed by sex.
Data distribution of continuous variables was checked using
skewness, kurtosis, and visual inspection of the histogram.
Continuous variables were presented as meanSD and com-
pared using Student t tests or medians (interquartile range
[IQR]) and compared using the Wilcoxon rank sum test, as
appropriate. Categorical variables were presented as numbers
(percentages) and compared using v2 or Fisher exact tests.
To assess the covariate-adjusted odds ratio (OR) with 95%
conﬁdence interval (CI) for the predictor female sex and to take
advantage of the longitudinal follow-up available in this cohort,
longitudinal mixed logistic regression analysis was performed
Clinical Perspective
What Is New?
• Women with atrial ﬁbrillation report more symptoms than
men, including a higher burden of palpitations, dyspnea,
fatigue, and dizziness.
• These ﬁndings persist after comprehensive adjustment and
during longitudinal follow-up.
What Are the Clinical Implications?
• Women with atrial ﬁbrillation have a substantially higher
symptom burden and lower health perception than men.
• Whether women should be considered more often for
interventions to reduce their symptom burden should be
studied in a randomized trial.
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using binary symptom-related variables as the outcome. To
account for the fact that observations from the same patients
are not independent of each other, we included patient identiﬁer
as a random effect into the model. Longitudinal mixed linear
regression with patient identiﬁer as a random effect was
performed to calculate ß coefﬁcients (95% CI) for continuous
outcome variables. All regression models were adjusted for a
predeﬁned set of covariates including baseline body mass
index, systolic blood pressure, heart rate, and updated infor-
mation on history of coronary heart disease, diabetes mellitus,
hypertension, heart failure, stroke, oral anticoagulation, infor-
mation on AF-related intervention (electrical cardioversion
and/or pulmonary vein isolation), current AF type (paroxysmal
or nonparoxysmal), smoking, and visit number. To assess the
potential inﬂuence of sex-speciﬁc differences in left ventricular
function on our ﬁndings, we performed a multivariable logistic
regression analysis with baseline data, which was additionally
adjusted for left ventricular ejection fraction in the subcohort for
which this information was available.
All statistical analyses were performed using SAS 9.4 (SAS
Institute). A 2-sided P<0.05 was considered to indicate
statistical signiﬁcance.
Results
Baseline characteristics are presented in Table 1. Overall, 454
(29.4%) study participants were women. Female partici-
pants were older than male participants (7011 versus
6712 years, P<0.0001) and more often had paroxysmal
AF (61% versus 54%, P=0.04), higher heart rate (7116 ver-
sus 6915 bpm, P=0.05), and higher systolic blood pressure
(13721 versus 13419 mm Hg, P=0.007). Male patients
were more likely to have a history of diabetes mellitus (15%
versus 10%, P=0.01) or myocardial infarction (14% versus 8%,
P=0.0009). Women had fewer AF-related interventions before
enrollment (31% versus 39%, P=0.002).
Symptoms According to AF Type
Patients with paroxysmal AF had more symptoms than patients
with persistent and permanent AF (80%, 76%, and 51%,
respectively, P<0.0001), as shown in Table 2. When comparing
individual symptoms according to AF type, palpitations, dizzi-
ness, and chest painweremore often reported in paroxysmal AF
patients (P<0.0001, P=0.009, and P=0.02), whereas dyspnea,
fatigue and effort intolerance were more prevalent in patients
with nonparoxysmal AF (all P<0.0001).
Symptoms According to Sex
Health perception and prevalence of various symptom
categories according to sex at baseline and up to 3 years of
follow-up are shown in Table 3. At baseline, health perception
on a VAS was signiﬁcantly worse in women compared with
men (70 [IQR: 50–80] versus 76 [IQR: 60–85], P<0.0001).
Women reported symptoms signiﬁcantly more often than men
(85% versus 68%, P<0.0001). When the different symptom
categories were assessed individually, women more often
indicated palpitations (65% versus 44%, P<0.0001), dizziness
(26% versus 14%, P<0.0001), fatigue (25% versus 19%,
P=0.006), and dyspnea (36% versus 22%, P<0.0001), whereas
men more often reported effort intolerance (14% versus 9%,
P=0.005). No signiﬁcant differences were observed for chest
pain (12% of women versus 9% of men, P=0.12) and syncope
(4% of women versus 3% of men, P=0.26).
Table 1. Baseline Characteristics According to Sex
Characteristic
Women
(n=454)
Men
(n=1088) P Value*
Age, y 70.410.7 67.211.9 <0.0001
Body mass index, kg/m2 26.65.7 27.44.3 0.007
Heart rate, beats/min 71.015.7 69.315.0 0.05
Systolic blood pressure,
mm Hg
136.821.4 133.718.9 0.007
Diastolic blood pressure,
mm Hg
78.513.4 79.012.8 0.5
Type of atrial fibrillation
Paroxysmal 275 (60.6) 584 (53.7) 0.04
Persistent 94 (20.7) 274 (25.2)
Permanent 85 (18.7) 229 (21.1)
Atrial flutter 64 (14.1) 228 (21.0) 0.002
History of myocardial
infarction
37 (8.2) 155 (14.3) 0.0009
History of stroke/TIA 54 (11.9) 141 (13.0) 0.6
History of hypertension 320 (70.5) 724 (66.5) 0.1
History of heart failure 81 (17.8) 233 (21.4) 0.1
History of diabetes mellitus 46 (10.1) 164 (15.1) 0.01
History of renal failure 61 (13.4) 167 (15.4) 0.3
Smoking status
Current 37 (8.2) 101 (9.3) <0.0001
History 151 (33.6) 565 (52.1)
Never 261 (58.1) 418 (38.6)
Aspirin as monotherapy 52 (11.6) 167 (15.7) 0.04
Oral anticoagulation 345 (76.0) 781 (72.0) 0.1
History of AF-related
intervention†
139 (30.7) 422 (38.9) 0.002
Data are meansSD or counts (percentages). Data may not sum to the given number
because of missing data. AF indicates atrial ﬁbrillation; TIA, transient ischemic attack.
*P-values were based on Student t tests or v2 tests, as appropriate.
†Intervention: either pulmonary vein isolation and/or electrical cardioversion.
DOI: 10.1161/JAHA.116.005401 Journal of the American Heart Association 3
Sex Differences in Symptoms Among AF Patients Blum et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
After 1 year of follow-up, health perception increased from
70 (IQR: 50–80) to 74 (IQR: 60–80) among women and from
76 (IQR: 60–85) to 80 (IQR: 65–90) among men, such that the
signiﬁcant sex-speciﬁc differences persisted (P<0.0001), as
shown in Table 3. Similar ﬁndings were observed after
2 years of follow-up (75 [IQR: 60–85] for women versus 80
[IQR: 65–90] for men, P=0.0004).
After 1 year of follow-up, the overall prevalence of
symptoms decreased to 49% among women and 33% among
men, but the sex-speciﬁc difference remained highly signif-
icant (P<0.0001). After 1 year of follow-up, women still had a
higher prevalence of palpitations (35% versus 21%, P<0.0001),
dyspnea (13% versus 9%, P=0.01), and dizziness (14% versus
7%, P<0.0001) compared with men. The higher symptom
burden in women also persisted after 2 years of follow-up
(48% versus 32% for men, P<0.0001) and after 3 years of
follow-up (41% versus 31%, P=0.02). Differences in symptom
categories remained generally consistent over time, although
not all comparisons were statistically signiﬁcant (Table 3).
Between baseline and 1 year of follow-up, a total of 405
(26.3%) patients had either pulmonary vein isolation or
electrical cardioversion, with similar percentages among
women and men (25.7% versus 30.6%, P=0.07). The symptom
burden declined overall by 28.4% among patients without
intervention and by 56.3% among those with intervention, as
shown in Table 4.
After multivariable adjustment in the longitudinal models,
female sex remained a strong predictor of overall symptoms
(OR: 2.6; 95% CI, 2.1–3.4; P<0.0001), palpitations (OR: 2.6;
95% CI, 2.1–3.2; P<0.0001), dizziness (OR: 2.9; 95% CI, 2.1–
3.9; P<0.0001), dyspnea (OR: 2.1; 95% CI, 1.6–2.8; P<0.0001),
fatigue (OR: 1.6; 95% CI, 1.2–2.2; P=0.0008), and chest pain
(OR: 1.8; 95% CI, 1.3–2.6; P=0.001), as shown in Table 5. No
association was observed for effort intolerance (OR: 0.7; 95%
CI, 0.5–1.0; P=0.051). Similarly, lower health perception
among women also persisted after multivariable adjustment
(ß=4.8; 95% CI, 6.5 to 3.1; P<0.0001).
Additional adjustment for left ventricular function among
those patients with this information available did not inﬂuence
our results, as shown in Table 6. In these baseline models,
female sex remained a signiﬁcant predictor of overall
symptoms (OR: 2.3; 95% CI, 1.3–4.0; P=0.004), palpitations
(OR: 2.3; 95% CI, 1.5–3.7; P=0.0002), dyspnea (OR: 1.8; 95%
CI, 1.2–2.8; P=0.008), fatigue (OR: 1.7; 95% CI, 1.1–2.6;
P=0.03), and dizziness (OR: 2.5; 95% CI, 1.5–4.1; P=0.0003).
Discussion
In this large prospective cohort study of patients with AF, we
found that women had substantially lower health perception
and a higher symptom burden compared with their male
counterparts. Most individual symptoms potentially related to
AF were more frequent in women than in men. These ﬁndings
remained statistically signiﬁcant after extensive multivariable
adjustment and persisted during prospective follow-up,
despite the fact that the overall symptom burden substantially
decreased over time.
Prior studies have shown that female participants with AF
were older and had more frequent paroxysmal AF and a higher
symptom burden than male participants.10,11,17,18 In a study
of patients with new-onset AF and normal echocardiogram,
Potpara et al showed that women more often had palpita-
tions, fatigue, and chest pain.17 Another study also found that
women had a more symptomatic European Heart Rhythm
Association class compared with men.11
Our data extend these ﬁndings in several respects. First,
the observed difference of 5 points in the VAS between men
and women is clinically meaningful; for example, the post-
procedural VAS score improved by 5 points in patients with
paroxysmal AF who underwent pulmonary vein isolation.19
Table 2. Symptom Status According to AF Type and Sex
Characteristic
Paroxysmal Persistent Permanent
P Value†Women Men P Value* Women Men P Value* Women Men P Value*
Any symptoms 247 (89.8) 442 (75.7) <0.0001 82 (87.2) 198 (72.3) 0.003 57 (67.1) 103 (45.0) 0.0005 <0.0001
Palpitations 210 (76.4) 328 (56.2) <0.0001 57 (60.6) 105 (38.3) 0.0002 29 (34.1) 50 (21.8) 0.03 <0.0001
Dyspnea 87 (31.6) 111 (19.0) <0.0001 42 (44.7) 86 (31.4) 0.02 33 (38.8) 40 (17.5) <0.0001 <0.0001
Fatigue 60 (21.8) 104 (17.8) 0.2 38 (40.4) 70 (25.6) 0.006 17 (20.0) 34 (14.9) 0.3 <0.0001
Dizziness 77 (28.0) 90 (15.4) <0.0001 23 (24.5) 35 (12.8) 0.007 16 (18.8) 22 (9.6) 0.03 0.009
Effort intolerance 18 (6.6) 84 (14.4) 0.0009 18 (19.2) 56 (20.4) 0.8 4 (4.7) 13 (5.7) 1.0 <0.0001
Chest pain 35 (12.7) 64 (11.0) 0.4 9 (9.6) 16 (5.8) 0.2 8 (9.4) 17 (7.4) 0.6 0.02
Syncope 12 (4.4) 19 (3.3) 0.4 3 (3.2) 6 (2.2) 0.7 2 (2.4) 4 (1.8) 0.7 0.2
Data are numbers (percentages). AF indicates atrial ﬁbrillation.
*P values were based on v2 or Fisher exact tests, as appropriate, and indicate differences in symptoms according to sex within the same atrial ﬁbrillation type.
†P values are based on v2 tests and indicate differences in symptoms across different atrial ﬁbrillation types.
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Given that this intervention is the most effective for symptom
control among patients with symptomatic paroxysmal AF, we
consider this difference as clinically meaningful. Second, we
showed that sex-speciﬁc differences persist over time,
despite the fact that a sizable number of enrolled participants
received AF-related interventions and that the overall symp-
tom burden decreased substantially. In contrast, our study is
in line with previous reports showing that symptom burden
among AF patients can be substantially reduced with currently
available treatment tools.20 Previous studies suggested that
women were less likely to receive AF-related interven-
tions,10,21,22 and our results are in line with this ﬁnding. The
totality of evidence suggests that symptomatic women should
be considered for interventions to reduce their symptom
burden. This hypothesis should be tested in a randomized
trial.
It is also interesting that patients with no interventions
during follow-up had considerably fewer symptoms at 1-year
follow-up. A possible explanation for this ﬁnding is the
development of tolerance to the arrhythmia over time. In
addition, this could reﬂect the dynamic nature of symptoms
and the many factors contributing to the interaction between
symptoms and AF.9 Improvement in antiarrhythmic or rate
control treatment may be another potential explanation.
Unfortunately, detailed data on changes in medical treatment
over time are currently unavailable in our database.
Third, our study is one of the ﬁrst to show that sex-speciﬁc
differences in AF-related symptoms persisted after multivari-
able adjustment. Most studies published on patients with AF
have shown important sex-speciﬁc differences in baseline
characteristics; therefore, adjustment for potential con-
founders in multivariable models is crucial to determine
whether differences in symptoms are related to differences in
baseline characteristics or whether there may be real sex-
speciﬁc differences in symptom status. Our study clearly
suggests that there are differences related to sex.
Several factors that might explain the persistent sex-
related differences have to be considered. Increased heart
rate is an important predictor of symptoms.15 Although we
adjusted for resting heart rate, women with paroxysmal AF
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Table 4. Symptom Status Over Time Stratiﬁed by
Intervention
Characteristic Symptoms Baseline
Symptoms at 1-Y
Follow-up P Value*
No intervention 652 (66.3) 373 (37.9) <0.0001
Intervention 376 (92.8) 148 (36.5) 0.008
P value* <0.0001 0.6
Data are numbers (percentages).
*P-values were based on v2 tests; intervention was pulmonary vein isolation and/or
electrical cardioversion between baseline and 1-year follow-up.
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may still have higher ambulatory heart rates, as has been
observed previously on Holter-ECG recordings in patients with
paroxysmal AF.23 A decreased vagal tone and a greater
prevalence of thyroid dysfunction in women may be a
mechanistic explanation for this observation.13 Total heart
rate variability was higher in postmenopausal women who
were on estrogen replacement therapy compared with those
without hormone therapy.24 In addition, resting and ambula-
tory heart rates were higher in young and healthy women,25
another observation that is in line with this hypothesis. Other
factors that may explain sex-speciﬁc differences but that were
not assessed in this study include drug adherence, emotional
stress, sleep quality, and sex-speciﬁc treatment strategies by
healthcare providers. Finally, residual confounding remains an
issue in every observational cohort.
Main strengths of this study are the large sample size of an
unselected and well-characterized AF population, the prospec-
tive follow-up with updating of symptom status and health
perception over time, and a clinically relevant main ﬁnding.
Several limitations need to be taken into account in the
interpretation of our ﬁndings. Given the observational study
design, we were not able to prove causality, and residual
confounding may be present despite extensive multivariable
adjustment, Nevertheless, our study suggests that differences
in symptoms are not explained by the covariates added to the
models. Finally, data on cardiac structure and function were
not systematically collected in this study. Adjustment for left
ventricular function among those with this information
available did not change our ﬁndings; however, differences
in cardiac function may still have inﬂuenced our results.
Patients with available information on left ventricular function
may be different from the overall study population and thus
may have experienced symptoms differently or for a reason
other than AF.
Conclusion
In this large prospective study of patients with AF, we found
that women had a signiﬁcantly higher symptom burden and
lower health perception than men. These ﬁndings persisted
Table 6. Differences in Symptom Status in Women Vs Men in
a Subset of Patients With Echocardiographic Baseline
Information
Characteristic OR (95% CI) P Value*
Any symptoms 2.3 (1.3; 4.0) 0.004
Palpitations 2.3 (1.5; 3.7) 0.0002
Dyspnea 1.8 (1.2; 2.8) 0.008
Fatigue 1.7 (1.1; 2.6) 0.03
Dizziness 2.5 (1.5; 4.1) 0.0003
Chest pain 1.7 (0.9; 3.1) 0.08
Effort intolerance 0.7 (0.4; 1.3) 0.3
Syncope 0.8 (0.2; 2.7) 0.7
ORs (95% CIs) are for women compared to men. CI indicates conﬁdence interval; OR,
odds ratio.
*P values were based on logistic regression. Models were adjusted for left ventricular
ejection fraction, age, body mass index, systolic blood pressure, heart rate (>100 and
<100 bpm), coronary heart disease (myocardial infarction, percutaneous transluminal
coronary angioplasty, or aortocoronary bypass), diabetes mellitus, hypertension, heart
failure, history of stroke, oral anticoagulation at baseline, history of intervention
(electrical cardioversion and/or pulmonary vein isolation), atrial ﬁbrillation type
(paroxysmal or nonparoxysmal), and current smoking.
Table 5. Differences in Symptom Status in Women Vs Men
Characteristic OR (95% CI) Univariate P Value* OR (95% CI) Multivariate P Value*
Any symptoms 2.6 (2.1–3.3) <0.0001 2.6 (2.1–3.4) <0.0001
Palpitations 2.6 (2.1–3.3) <0.0001 2.6 (2.1–3.2) <0.0001
Dizziness 2.7 (2.0–3.6) <0.0001 2.9 (2.1–3.9) <0.0001
Dyspnea 2.2 (1.7–2.8) <0.0001 2.1 (1.6–2.8) <0.0001
Fatigue 1.5 (1.2–2.0) 0.0014 1.6 (1.2–2.2) 0.0008
Chest pain 1.8 (1.3–2.5) 0.0009 1.8 (1.3–2.6) 0.001
Effort intolerance 0.6 (0.4–0.8) 0.002 0.7 (0.5–1.0) 0.051
b (95% CI) P Value† b (95% CI) P Value†
Health perception, 0–100 4.5 (6.3 to 2.7) <0.0001 4.8 (6.5 to 3.1) <0.0001
ORs (95% CIs) are for women compared with men. P values were based on mixed logistic regression models or mixed linear models, as appropriate. Univariate models were adjusted for
visit number; multivariable models were adjusted for baseline body mass index, systolic blood pressure, heart rate (>100 and <100 bpm), and updated information on age, current
smoking, oral anticoagulation, intervention (pulmonary vein isolation and/or electrical cardioversion), coronary heart disease (myocardial infarction, percutaneous transluminal coronary
angioplasty, or aortocoronary bypass), diabetes mellitus, hypertension, heart failure, history of stroke, atrial ﬁbrillation type (paroxysmal or nonparoxysmal), and visit number. CI indicates
conﬁdence interval; OR, odds ratio.
*Mixed logistic regression model.
†
Mixed linear model.
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over time and after comprehensive multivariable adjustment.
Future studies need to elaborate the mechanisms underlying
these important differences.
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